MSON Misonix Inc

On June 3, 2019, Misonix, Inc. (the “Misonix”) issued a press release announcing that it received 510(k) clearance by the U.S. Food and Drug Administration (“FDA”) for Nexus, its revolutionary ultrasonic surgical platform. Misonix expects to commence the commercialization of the Nexus platform in the United States in July.

The press release of Misonix announcing the FDA’s 510(k) clearance of Nexus is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Forward Looking Statements

This communication contains forward-looking statements, which address a variety of subjects including, for example, our expected timeline of commercialization of the Nexus platform. Statements that are not historical facts, including statements about our beliefs, plans and expectations, are forward-looking statements. Such statements are based on our current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. Important factors and uncertainties that could cause actual results to differ materially from those described in these forward-looking statements include, but are not limited to, the risk that our launch of Nexus may not occur on the timeline we expect. For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to Misonix’s filings with the SEC, including the risk factors contained in Misonix’s most recent Quarterly Reports on Form 10-Q and Annual Report on Form 10-K. Forward-looking statements represent management’s current expectations and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.